How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study

References

• Atefi, M., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., … Ribas, A. (2011). Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One, 6(12), e28973. doi:10.1371/journal.pone.0028973
   PubMed Web of Science ®Google Scholar
• Berendsen, H. J. C., Postma, J. P. M., Gunsteren, W. F. V., Dinola, A., & Haak, J. R. (1984). Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics, 81(8), 3684–3690. doi:10.1063/1.448118
   Web of Science ®Google Scholar
• Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., … Schwede, T. (2014). SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Research, 42(W1), W252–W258. doi:10.1093/nar/gku340
   PubMed Web of Science ®Google Scholar
• Blacklock, K., & Verkhivker, G. M. (2014). Computational modeling of allosteric regulation in the hsp90 chaperones: A statistical ensemble analysis of protein structure networks and allosteric communications. PLoS Computational Biology, 10(6), e1003679. doi:10.1371/journal.pcbi.1003679
   PubMed Web of Science ®Google Scholar
• Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., … Nolop, K. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467(7315), 596–599.
   PubMed Web of Science ®Google Scholar
• Brennan, D. F., Dar, A. C., Hertz, N. T., Chao, W. C., Burlingame, A. L., Shokat, K. M., & Barford, D. (2011). A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature, 472(7343), 366–369. doi:10.1038/nature09860
   PubMed Web of Science ®Google Scholar
• Carlino, M. S., Fung, C., Shahheydari, H., Todd, J. R., Boyd, S. C., Irvine, M., … Rizos, H. (2015). Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clinical Cancer Research, 21(1), 98. doi:10.1158/1078-0432.CCR-14-0759
   PubMed Web of Science ®Google Scholar
• Cuadrado, A., & Nebreda, A. R. (2010). Mechanisms and functions of p38 MAPK signalling. The Biochemical Journal, 429(3), 403–417. doi:10.1042/BJ20100323
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092. doi:10.1063/1.464397
   Web of Science ®Google Scholar
• Dhomen, N., & Marais, R. (2007). New insight into BRAF mutations in cancer. Current Opinion in Genetics & Development, 17(1), 31–39. doi:10.1016/j.gde.2006.12.005
   PubMed Web of Science ®Google Scholar
• Doncheva, N. T., Klein, K., Domingues, F. S., & Albrecht, M. (2011). Analyzing and visualizing residue networks of protein structures. Trends in Biochemical Sciences, 36(4), 179–182. doi:10.1016/j.tibs.2011.01.002
   PubMed Web of Science ®Google Scholar
• Dong, C., Davis, R. J., & Flavell, R. A. (2002). MAP kinases in the immune response. Annual Review of Immunology, 20(1), 55–72. doi:10.1146/annurev.immunol.20.091301.131133
   PubMedGoogle Scholar
• Fischmann, T. O., Smith, C. K., Mayhood, T. W., Myers, J. E., Reichert, P., Mannarino, A., … Madison, V. S. (2009). Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry, 48(12), 2661–2674. doi:10.1021/bi801898e
   PubMed Web of Science ®Google Scholar
• Floyd, R. W. (1962). Algorithm 97, shortest path algorithms. Communications of the ACM, 5(6), 345. doi:10.1145/367766.368168
   Web of Science ®Google Scholar
• Gao, J., Chang, M. T., Johnsen, H. C., Gao, S. P., Sylvester, B. E., Sumer, S. O., … Sander, C. (2017). 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. Genome Medicine, 9(1), 4. doi:10.1186/s13073-016-0393-x
   PubMedGoogle Scholar
• Grisham, R. N., Sylvester, B. E., Won, H., McDermott, G., DeLair, D., Ramirez, R., … Iyer, G. (2015). Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer. Journal of Clinical Oncology, 33(34), 4099–4105. doi:10.1200/JCO.2015.62.4726
   PubMed Web of Science ®Google Scholar
• Guan, S., Zhao, L., Jin, H., Shan, N., Han, W., Wang, S., … Shan, Y. (2016). Binding modes of phosphotriesterase-like lactonase complexed with δ-nonanoic lactone and paraoxon using molecular dynamics simulations. Journal of Biomolecular Structure & Dynamics, 35(2), 1. doi:10.1080/07391102.2016.1142899.
   PubMed Web of Science ®Google Scholar
• Hagberg, A. & Swart, P. (2008). Rewiring networks for synchronization. Chaos, 18(3), 037105. doi:10.1063/1.2975842
   Google Scholar
• Hanks, S. K., & Hunter, T. (1995). Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. The FASEB Journal, 9(8), 576–596. doi:10.1096/fasebj.9.8.7768349
   PubMed Web of Science ®Google Scholar
• Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, J. G. E. M. (2008). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 4(1), 1463–1472. doi:10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Google Scholar
• Hess, B., & van der Vegt, N. F. A. (2006). Hydration thermodynamic properties of amino acid analogues: A systematic comparison of biomolecular force fields and water models. The Journal of Physical Chemistry B, 110(35), 17616–17626. doi:10.1021/jp0641029
   PubMed Web of Science ®Google Scholar
• Hsieh, H. P., & Hsu, J. T. (2007). Strategies of development of antiviral agents directed against influenza virus replication. Current Pharmaceutical Design, 13(34), 3531. doi:10.2174/138161207782794248
   PubMed Web of Science ®Google Scholar
• Hubbard, S. R. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. The EMBO Journal, 16(18), 5572–5581. doi:10.1093/emboj/16.18.5572
   PubMed Web of Science ®Google Scholar
• Lee, L. J., & Mccubrey, J. A. (2002). Targeting the Raf kinase cascade in cancer therapy–novel molecular targets and therapeutic strategies. Expert Opinion on Therapeutic Targets, 6(6), 659. doi:10.1517/14728222.6.6.659
   PubMedGoogle Scholar
• Knighton, D. R., Zheng, J. H., Eyck, L. T., Ashford, V. A., Xuong, N. H., Taylor, S. S., … Sowadski, J. M. (1991). Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science, 253(5018), 407–414. doi:10.1126/science.1862342
   PubMed Web of Science ®Google Scholar
• Kolch, W. (2005). Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nature Reviews Molecular Cell Biology, 6(11), 827–837. doi:10.1038/nrm1743
   PubMed Web of Science ®Google Scholar
• Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., … Wang, W. (2000). Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research, 33(12), 889–897. doi:10.1021/ar000033j
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., & Lynn, A. (2014). g_mmpbsa–a GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. doi:10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Ma, W., & Quirion, R. (2005). The ERK/MAPK pathway, as a target for the treatment of neuropathic pain. Expert Opinion on Therapeutic Targets, 9(4), 699–713. doi:10.1517/14728222.9.4.699
   PubMed Web of Science ®Google Scholar
• Maisuradze, G. G., Liwo, A., & Scheraga, H. A. (2010). Relation between free energy landscapes of proteins and dynamics. Journal of Chemical Theory and Computation, 6(2), 583–595. doi:10.1021/ct9005745
   PubMed Web of Science ®Google Scholar
• Meier, C., Brookings, D. C., Ceska, T. A., Doyle, C., Gong, H., McMillan, D., … Allen, R. A. (2012). Engineering human MEK-1 for structural studies: A case study of combinatorial domain hunting. Journal of Structural Biology, 177(2), 329–334. doi:10.1016/j.jsb.2012.01.002
   PubMed Web of Science ®Google Scholar
• MiniBoo, N. E. C., Aguilar-Arevalo, A. A., Anderson, C. E., Bazarko, A. O., Brice, S. J., Brown, B. C., … Zimmerman, E. D. (2010). First measurement of the Muon neutrino charged current quasielastic double differential cross section. Physical Review D, 81, 092005. doi:10.1103/PhysRevD.81.092005
   Web of Science ®Google Scholar
• Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., … Antonarakis, S. E. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nature Genetics, 44(2), 133–139. doi:10.1038/ng.1026
   Web of Science ®Google Scholar
• Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011). RAS oncogenes: Weaving a tumorigenic web. Nature Reviews Cancer, 11(11), 761–774. doi:10.1038/nrc3106
   PubMed Web of Science ®Google Scholar
• Rogers, D. F. (2005). The role of airway secretions in COPD: Pathophysiology, epidemiology and pharmacotherapeutic options. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2(3), 341–353. doi:10.1080/15412550500218098
   Google Scholar
• Roskoski, R. (2010). RAF protein-serine/threonine kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 399(3), 313–317. doi:10.1016/j.bbrc.2010.07.092
   PubMed Web of Science ®Google Scholar
• Schuttelkopf, A. W., & van Aalten, D. M. F. (2004). PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica Section D Biological Crystallography, 60(8), 1355–1363. doi:10.1107/S0907444904011679
   PubMedGoogle Scholar
• Sebolt-Leopold, J. S., & Herrera, R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Reviews Cancer, 4(12), 937–947. doi:10.1038/nrc1503
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold, J. S., Herrera, R., & Ohren, J. F. (2007). The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment. Recent Results Cancer Research, 172, 155–167. doi:10.1007/978-3-540-31209-3_9
   PubMedGoogle Scholar
• Senawong, T., Phuchareon, J., Ohara, O., Mccormick, F., Rauen, K. A., & Tetsu, O. (2007). Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: Implications for therapeutic options. Human Molecular Genetics, 17(3), 419. doi:10.1093/hmg/ddm319
   PubMed Web of Science ®Google Scholar
• Sethi, A., Eargle, J., Black, A. A., & Luthey-Schulten, Z. (2009). Dynamical networks in tRNA:protein complexes. Proceedings of the National Academy of Sciences of the United States of America, 106(16), 6620–6625. doi:10.1073/pnas.0810961106
   PubMed Web of Science ®Google Scholar
• Shao, Y., & Aplin, A. E. (2010). Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Research, 70(16), 6670. doi:10.1158/0008-5472.CAN-09-4471
   PubMed Web of Science ®Google Scholar
• Shi, H., Kong, X., Ribas, A., & Lo, R. S. (2011). Combinatorial treatments that overcome PDGFRÎ2-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Research, 71(15), 5067–5074. doi:10.1158/0008-5472.CAN-11-0140
   PubMed Web of Science ®Google Scholar
• Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B., Egyhazi, S., … Nathanson, K. L. (2008). Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas. Molecular Cancer Therapeutics, 7(9), 2876. doi:10.1158/1535-7163.MCT-08-0431
   PubMed Web of Science ®Google Scholar
• Stetz, G., & Verkhivker, G. M. (2016). Probing allosteric inhibition mechanisms of the Hsp70 chaperone proteins using molecular dynamics simulations and analysis of the residue interaction networks. Journal of Chemical Information and Modeling, 56(8), 1490. doi:10.1021/acs.jcim.5b00755
   PubMed Web of Science ®Google Scholar
• Taylor, S. S., & Kornev, A. P. (2011). Protein kinases: Evolution of dynamic regulatory proteins. Trends in Biochemical Sciences, 36(2), 65–77. doi:10.1016/j.tibs.2010.09.006
   PubMed Web of Science ®Google Scholar
• Thompson, N., & Lyons, J. (2005). Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Current Opinion in Pharmacology, 5(4), 350–356. doi:10.1016/j.coph.2005.04.007
   PubMed Web of Science ®Google Scholar
• Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., … Herlyn, M. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 18(6), 683–695. doi:10.1016/j.ccr.2010.11.023
   PubMed Web of Science ®Google Scholar
• Wortzel, I., & Seger, R. (2011). The ERK cascade: Distinct functions within various subcellular organelles. Genes & Cancer, 2(3), 195. doi:10.1177/1947601911407328
   PubMedGoogle Scholar
• Xie, J., Ajibade, A. O., Ye, F., Kuhne, K., & Gao, S. J. (2008). Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology, 371(1), 139–154. doi:10.1016/j.virol.2007.09.040
   PubMed Web of Science ®Google Scholar
• Xing, F., Persaud, Y., Pratilas, C. A., Taylor, B. S., Janakiraman, M., She, Q.-B., … Solit, D. B. (2012). Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene, 31(4), 446. doi:10.1038/onc.2011.250
   PubMed Web of Science ®Google Scholar
• Zebisch, A., Czernilofsky, A. P., Keri, G., Smigelskaite, J., Sill, H., & Troppmair, J. (2007). Signaling through RAS-RAF-MEK-ERK: From basics to bedside. Current Medicinal Chemistry, 14(5), 601. doi:10.2174/092986707780059670
   PubMed Web of Science ®Google Scholar
• Zheng, J., Trafny, E. A., Knighton, D. R., Xuong, N., Taylor, S. S., Ten Eyck, L. F., & Sowadski, J. M. (2010). 2.2 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallographica, 49(3), 362–365.
   Google Scholar